VBI Vaccines Stock Is Trading Higher On Encouraging Data From COVID-19 Vaccine Candidate Trial

VBI Vaccines Inc VBIV has announced positive Phase 1 data from its Phase 1/2 trial evaluating its enveloped virus-like particle (eVLP) COVID-19 vaccine candidate VBI-2902a.
VBI-2902a was well-tolerated, with no safety signals observed.
After two doses, VBI-2902a induced neutralization titers in 100% of participants, with 4.3x higher geometric mean titer (GMT) than that of the convalescent serum panel (n=25).
After two doses, VBI-2902a also induced antibody binding titers in 100% of participants, with a GMT of 4,047 units/mL, 5.0x the GMT of the convalescent serum panel.
Data from this study also support the assessment of a one-dose booster regimen in seropositive individuals.
The company will initiate the next phase of the ongoing adaptive Phase 1/2 study expected in Q3 2021 with the VBI-2905a candidate directed against the COVID-19 Beta (B.1.351) variant of concern.
H1 2022: Expected initiation of the first study of VBI's multivalent candidate, designed to increase the breadth of protection against COVID-19.
VBI Vaccines will host a conference call and webcast today at 8:30 AM ET.
Price Action: VBIV shares are up 4.61% at $4.20 during the premarket session on the last check Tuesday.